

Horizon 2020

Societal Challenge 1: Health, demographic change and wellbeing



What is Horizon 2020?



The EU's 2014-20 programme for research & innovation
77 billion euros over 7 years

- Responding to the economic crisis to invest in future jobs and growth
- Addressing people's concerns about their livelihoods, safety and environment
- Strengthening the EU's global position in research, innovation and technology



Horizon 2020 - what's new?

- A single programme bringing together three separate programmes/initiatives*
- Coupling research to innovation from research to retail, all forms of innovation
- Focus on societal challenges facing European society e.g. health and ageing, clean energy and transport
- Simplified access, for all companies, universities, institutes in all EU countries and beyond

^{*} The 7th Research Framework Programme (FP7), innovation aspects of Competitiveness and Innovation Framework Programme (CIP), EU contribution to the European Institute of Innovation and Technology (EIT)



Three priorities





Societal challenges

29 679 million EUR

1. Health, demographic change and wellbeing	7 472
2. Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the Bioeconomy	3 851
3. Secure, clean and efficient energy	5 931
4. Smart, green and integrated transport	6 339
5. Climate action, environment, resource efficiency and raw materials	
6. Inclusive, innovative and reflective societies	1 310
7. Secure societies	1 695







The challenges



- Ageing population
- Increased disease burden
- Sustainability and equality of health & care systems



A new approach



Challenge-driven

Broad topics

Less prescriptive topic texts

Two-year work programme

Stronger focus on end users





More opportunities for SMEs



- Some 20% of the total budget for societal challenges/LEITs to go to SMEs
- Simplification a great benefit to SMEs
- 'Access to risk finance' with strong SME focus (debt and equity facility)
- A new SME instrument





SME instrument

Idea

Concept & Feasibility Assessment

Phase 1

Phase 2

Innovation R&D activities

Phase 3

Commercialisation

Market



- Feasibility of concept
- Risk assessment
- IP regime
- Partner search
- Design study

- Development, prototype, testing
- Miniaturisation/design
- Clinical trials
- Etc.

- Facilitate access to private finance
- Support via networking, training, coaching, knowledge sharing, dissemination

Lump sum: ~ 50.000 € ~ 6 months

EU funding: 1 to 5 M€ 12 to 36 months

No direct funding



Getting you started faster

- A single set of simpler and more coherent participation rules
- Just 2 funding rates (70% / 100%)
- Single flat rate (25%) for overhead or 'indirect costs'
- Simpler financial regulation to come
- 8 months time-to-grant target









Understanding the call topics: example

PHC 2 – 2015: Understanding diseases: system

Specific challenge: The development of new improved understanding of the often very cor (bio) medicine approaches have the potential to t of a variety of biological and medical research de collaborative approach is required to assemble the biology, medicine, mathematics, computational t medicine approaches.

Scope: Proposals should focus on new avenues phenotypes in multifactorial diseases and/or development/optimisation and/or application of s of biomedical and clinical data to produce or refi computational and mathematical approaches. The validated in well-phenotyped patient cohorts, tak potential thoroughly investigated.

The Commission considers that proposals reques EUR 4 and 6 million would allow this speci Nonetheless, this does not preclude submission amounts.

Expected impact: This will provide:

- Leverage of existing investments in Eur
- New directions for better disease detecti
- Systems medicine tools and approaches t which represent an improvement over e

Type of action: Research and Innovation action

'PHC 2 - 2015'

'Specific challenge'

'Scope'

'Expected impact'

'Type of action'



The Work Programme 2014/15 in brief



European

Commission

Call 'personalising health and care' Seven focus areas

- Understanding health, ageing & disease
- Effective health promotion, disease prevention, preparedness and screening
- Improving diagnosis
- Innovative treatments and technologies
- Advancing active and healthy ageing
- Integrated, sustainable, citizen-centred care
- Improving health information, data exploitation and providing an evidence base for health policies and regulation



Call 'personalising health and care' Seven areas

- Understanding health, ageing & disease
 - Determinants, risk factors, systems medicine, common mechanisms and co-morbidity
- Effective health promotion, disease prevention, preparedness and screening
 - Environment and health interventions, -omics for personalised medicine, screening programmes, zoonoses, vaccine platforms
- Improving diagnosis
 - In vitro, medical imaging, validation of biomarkers

Call 'personalising health and care' Seven areas

- Innovative treatments and technologies
 - Clincal trials, rare diseases, regenerative medicine, advanced therapies, comparative effectiveness in the elderly, establishing effectiveness in the paediatric population
- Advancing active and healthy ageing
 - Robotics, cognitive impairment, risk detection, mental wellbeing in ageing population
- Integrated, sustainable, citizen-centred care
 - New models for health and care systems, personalised medicine pilots, ICT systems for integrated care, mHealth, public procurement of eHealth

Call 'personalising health and care' Seven areas

- Improving health information, data exploitation and providing an evidence base for health policies and regulation
 - Digital patient, foresight, bioinformatics, predictive human safety testing, eHealth interoperability



Call for 'co-ordination activities' Support for European and International Initiatives

- European Innovation Partnership on Active and Healthy Ageing
- Global Alliance for Chronic Diseases (GACD) Diabetes (2014)
- Joint Programming Initiative 'More Years, Better Life's (2014)
- Joint Programming Initiative on neurodegenerative diseases (JPND, 2014)
- Global Research Collaboration for Infectious Disease Preparedness (2014)
- European Reference Networks (2015)



Call for 'co-ordination activities' Completing the European Research Area

- Joint Programming Initiative on neurodegenerative diseases (JPND, 2014)
- Translational cancer research (2014)
- Systems medicine for clinical needs (2014)
- Rare diseases (2014)
- 2015: Brain-related disorders, antimicrobial resistance, cardiovascular diseases



Applying for funding – the process in brief


Publication of the calls

Time to prepare the proposal

Submission of proposals

Evaluation

Signature grant agreement



Information on the outcome of the evaluator



Participant portal – your one-stop shop

- Topics
- Documents
- Rules for participation



http://ec.europa.eu/research/participants/portal



Other useful websites

CORDIS (FP7)



http://cordis.europa.eu/home_en.html

Health research on Europa



http://ec.europa.eu/research/health

eHealth research on Europa



http://ec.europa.eu/digital-agenda/en/life-and-work/living-healthy-ageing-well

Fit for Health: Partner search



http://www.fitforhealth.eu/



Next steps

Submission deadlines for your proposals	Two-stage topics: 11 March & 19 August
	Single stage topics: 15 April
	SME instrument:
	 Phase 1: 3 cut-off dates: 18/06; 24/09; 17/12/2014
	 Phase 2: 2 cut-off dates: 09/10; 17/12/2014
Horizon 2020 national launch events	Final stages http://ec.europa.eu/programmes/horizon2020/en/newsroom/573%20550/
National / regional Infodays	Check with your national contact points http://ec.europa.eu/research/participants/portal/desktop/en/support/national_contact_points.html

Health, Demographic Change and Wellbeing Dr. Ghenadie CUROCICHIN State University of Medicine and Pharmaceutics N.Testemitanu +37369149267, ghenadie.curocichin@h2020.md







In the Pipeline: IMI2


- Commission proposal from 10 July, legislative process ongoing
- Mission: create an even more powerful research and innovation machine, with broader objectives and a wider range of activities and partners
- Proposed budget: €3.45 billion, equally shared between public and private partners
- Key objectives:
 - Pave the way for the breakthrough vaccines, medicines and treatments which we will need in the near future
 - Enable top quality research and innovations with great public health benefits and commercial possibilities





In the Pipeline: EDCTP2

- Broader scope
 - + neglected infectious diseases, all clinical phases, diagnostics and delivery optimisation
- More EU co-funding almost €700 million
- Longer duration10 years







In the Pipeline: AAL2

- AAL: €600 million from 22 EU countries + EU funding of €150 million
- Scope of AAL 2: Market-oriented ICT research in assisted living technologies & services
- New instruments: e.g. prizes or innovation grants
- More EU co-funding: Participating countries pay €225 million (indicative), EU pays up to €175 million (indicative, ~40% of total public funding)







